GNPX Genprex Inc.

Genprex Inc is a clinical stage gene therapy company. It develops therapies that carry cancer-fighting genes. Its initial product candidate is Oncoprex.

$3.39
As of 06/18/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/29/2018
Outstanding shares:  47,363,729
Average volume:  485,043
Market cap:   $165,299,414
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    372446104
ISIN:        US3724461047
Sedol:      BFMNZZ1
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   3.18
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy